Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Pharmaceutical industry news

Show

From To
Merck's lead HIV play hits the mark in first phase 3 challenge

Merck has taken a big step toward getting its lead HIV candidate doravirine to market, setting up a showdown with Johnson & Johnson's big-selling Prezista.

Published
19 February 2017
From
FierceBiotech
Pharma industry shuns Trump push for radical shift at FDA

President Donald Trump's vow to roll back government regulations at least 75 percent is causing anxiety for some pharmaceutical executives that a less robust Food and Drug Administration would make it harder to secure insurance coverage for pricey new medicines.

Published
15 February 2017
From
Reuters
Could Trump’s Plan To Deregulate The FDA Benefit HIV Treatment?

Matthew Kavanagh of Health GAP, which advocates for affordable HIV/AIDS drugs, says Trump was right about one thing: “The way to drive down drug prices is to import generic versions of these drugs to allow for competition."

Published
13 February 2017
From
New Now Next
Gilead to use dating sites, Tumblr, and Snapchat in Truvada strategy

Using platforms like Tumblr and Snapchat may help the company raise awareness about the preventative HIV drug Truvada among a population of people who don't engage with the healthcare system in traditional ways, Gilead said during a call with investors on Tuesday.

Published
13 February 2017
From
Medical Marketing & Media
Trump loses backbone on drug prices. Is there a pill for that?

Amid all the kerfuffle in the last week over immigration, the Supreme Court, Iran and Arnold Schwarzenegger’s TV ratings, too little attention was paid to an extraordinary meeting at the White House at which President Trump reneged on a campaign promise and sold out millions of “forgotten” Americans to giant drug companies.

Published
07 February 2017
From
Washington Post
Dear President Trump: Your big idea on drug pricing is half-baked

When you met with several pharma executives last week, you complained about “astronomical” drug prices and promised to cut regulations so medicines could be approved faster. You promised, without specifics, to use trade policies so that foreign countries would pay their “fair share.”

Published
07 February 2017
From
STAT
Trump has big plans to fix drug prices. Here’s your reality check.

President Trump has ambitious plans to overhaul the drug market, speeding approvals while bringing down prices. It sounds great. But soundbites can be deceiving. So we gave Trump’s rhetoric a reality check.

Published
01 February 2017
From
STAT
Trump wants to blow up the FDA. The drug industry? Not so much.

President Donald Trump wants to remake the Food and Drug Administration. But does anyone really want a deregulated FDA? STAT canvassed biopharma insiders, physicians, Wall Street analysts, and FDA veterans. Their verdict: Trump’s plan sounds like a solution in search of a problem.

Published
01 February 2017
From
STAT
English High Court refers Truvada SPC case to EU Court of Justice

The English High Court has referred a supplementary protection certificate (SPC) dispute over Truvada (emtricitabine/tenofovir) to Europe’s highest court, the Court of Justice of the European Union (CJEU). The SPC if granted would effectively extend Gilead's patent rights over Truvada till 2020. If rejected Truvada's patent protection would expire at the same time as tenofovir's, i.e. this summer. For the full judgment, see http://www.bailii.org/ew/cases/EWHC/Patents/2017/13.html#para8

Published
27 January 2017
From
Life Sciences Intellectual Property Review (free subscription needed to read)
Public Health Groups Welcome Johns Hopkins University and Medicines Patent Pool Agreement for Development of Promising New TB Drug

While deal marks a critical step in the fight against TB, health groups warn that the deal lacks safeguards that would ensure worldwide affordability.

Published
26 January 2017
From
MSF Access Campaign
← First12345...93Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.